ClinicalTrials.gg
RecruitingNCT07118410ERFOCARDUpdated Oct 21, 2026

Resistance Exercise With Blood Flow Restriction by Vascular Occlusion on Myocardial Function in Heart Failure With Reduced Ejection Fraction

An interventional study of Application of a vascular restriction device during resistance training in Heart Failure and Ventricular Function, Left, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 21, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 448 studies in Heart Failure with a site in France — 90 open to participants now, 116 under way, 16 of them phase 3. Heart Failure · France.

Planned enrollment
231st of 282
38 · median 196
Started
2025
with 28 others
No phase
176 of 448
47 open now
Primary completion
2027-12
later than 65 of 115 live
Registered
407th of 448
by date

Among the 448 studies in Heart Failure with a site in France, this one is the 231st largest by planned enrollment of the 282 interventional ones that give a count, is one of 29 that started in 2025, is one of 176 with no phase, reaches primary completion later than 65 of the 115 other live ones, and was the 407th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

90 of the 448 studies in Heart Failure with a site in France are open now. Recruiting first, the newest first:

84 more — sign in →

All 90 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Heart Failure with a site in France, or all of them as a file.
02

Study summary

Exercise is essential in cardiac rehabilitation for heart failure patients.Aerobic training and resistance training are both recommended. Resistance training improves muscle mass and strength and also improves the remodeling of cardiac function, thus reducing exercise intolerance in these patients. However, to obtain these adaptations, resistance training must be done at moderate to high intensities, which cannot always be sustained by the most fragile and deconditioned patients, such as those with reduced ejection fraction (Heart failure with reduced Ejection Fraction).

Blood flow restriction (BFR) by vascular occlusion training is an interesting alternative to conventional resistance training for these deconditioned patients. Preclinical and clinical studies have shown that, for low-intensity regimens, resistance training and blood flow restriction by vascular occlusion improves muscle strength and left ventricular function, unlike resistance training alone. Tissue hypoxemia, initiated by vascular occlusion and exacerbated by maintenance of exercise, is a key element in the peripheral adaptations documented in blood flow restriction, triggering a cascade of signaling pathways involving neurohumoral factors in particular, with effects both locally (i.e. striated skeletal muscle) and remotely, on the myocardium among others. The feasibility and safety of blood flow restriction in heart failure patients has been well demonstrated. Left ventricle ejection fraction remains a very global functional index, with poor reproducibility influenced by cardiac load conditions, making it impossible to draw any conclusions as to possible improvements in myocardial function, linked to changes in intrinsic tissue decontractility/relaxation properties. New cardiac imaging techniques like Speckle Tracking Echography have made it possible to assess the effects of blood flow resistance on myocardial function but so far no studies have used these tools to compare the effects of BFR+resistance training and resistance training alone on myocardial function in heart failure patients. It is suggested that resistance training combined with blood flow resistance could further improve cardiac and muscular function compared with resistance training alone, by activating neurohumoral mediators, like certain micro ribonucleic acids.

Read the detailed description

Physical exercise is an essential part of cardiac rehabilitation for heart failure patients. In addition to aerobic training, resistance training is now recommended by scientific societies. Clinical studies report that resistance training contributes not only to peripheral reconditioning, with improved muscle mass and strength, but also to central reconditioning, with improved remodeling and cardiac function, thus reducing the exercise intolerance of heart failure patients. These favorable adaptations are achieved, however, on condition that RT is performed at moderate to high intensities (e.g. >75-80% of maximal repetition), intensities that cannot always be sustained by the most fragile and deconditioned patients, such as those with heart failure with reduced ejection fraction. The guidelines recommend intensities of 40% or less of repetition maximum.

Blood flow restriction (BFR) by vascular occlusion training is an interesting alternative to conventional resistance training, particularly for these most deconditioned patients. Preclinical and clinical studies have clearly established that for low-intensity regimens (around 40% of maximal repetition, an intensity well tolerated by the most fragile patients), resistance training+BFR improves muscle strength and left ventricular function, unlike resistance training alone. Tissue hypoxemia, initiated by vascular occlusion and exacerbated by maintenance of exercise, is a key element in the peripheral adaptations documented in BFR, triggering the activation of a cascade of signaling pathways involving neurohumoral factors in particular, with effects both locally (i.e. striated skeletal muscle) and remotely, on the myocardium among others. The feasibility and safety (i.e. no reported adverse events) of BFR in heart failure patients has been well demonstrated.

Left ventricular ejection fraction remains a very global functional index, with poor reproducibility and influenced by cardiac load conditions, making it impossible to draw any conclusions as to possible improvements in myocardial function, linked to changes in intrinsic tissue decontractility/relaxation properties. Innovative cardiac imaging techniques, such as Speckle Tracking Echography, now enable a detailed assessment of the effects of BFR on myocardial function. However, no study has yet used these tools to compare the effects of BFR+resistance training and resistance training alone on myocardial function in heart failure with reduced ejection patients. It is hypothetically suggested that resistance training combined with BFR could further improve cardiac and muscular function compared with resistance training alone, thanks to the activation of neurohumoral mediators, such as certain micro ribonucleic acids.

03

Conditions studied

  • Heart Failure
  • Ventricular Function, Left

Browse trials for

Keywords

  • Cardiac rehabilitation
  • Resistance training
  • Blood flow restriction
  • Cardiac function
  • Speckle tracking echography
  • Heart failure with reduced ejection fraction
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≤ 50%
  • Patients with an indication for cardiovascular rehabilitation in the first stay or not (according to national recommendations, as soon as possible after an exacerbation or at any time in a patient with chronic heart failure) (Bigot et al., 2024)
  • No medical to physical activity
  • Patient has given free and and signed the consent form
  • Patient affiliated with or benefiting from a health insurance scheme

Exclusion criteria

Exclusion Criteria:

  • Patient participating in another Category I interventional study, or having participated in another interventional study in the last month
  • Patient in an exclusion period determined by a previous study
  • Patient under court protection, guardianship or curatorship
  • Unable to provide , or patient refuses to sign consent form
  • Pregnant, parturient or breast-feeding patient
  • Moderate to severe peripheral arterial disease. Arterial Doppler scan for arterial stenosis, with measurement of femoral and distal flows.
  • Active or recent deep vein thrombosis. Check with venous Doppler ultrasound, looking for venous compressibility at the roots of the thighs, and 4-point venous ultrasound.
  • Medication known to alter the effects of ischemic conditioning (cyclosporine, glibenclamide).
  • Uncontrolled arterial hypertension
  • Severe valvular disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
38 participants (estimated)

Study arms

  • No intervention
    RT control group

    Patients on resistance training only. Patients in this group will receive 4 weeks of cardiac rehabilitation with 6 sessions/week, 2 sessions of aerobic training on a cycloergometer and 4 sessions of resistance training

  • Experimental
    RT+BFR group

    Patients on resistance training combined with blood flow restriction. Sessions will consist of 30 repetitions, followed by 3 sets of 15 repetitions at 40% 1-MR (maximal repetition), interspersed with 60 sec of recovery. An arterial occlusion pressure of 50% of systolic pressure will be maintained constant using a digital tourniquet. The cuff will be deflated during the recovery phases.

    Device: Application of a vascular restriction device during resistance training

Interventions

  • DeviceApplication of a vascular restriction device during resistance training

    In the BFR-RT group, sessions will consist of 30 repetitions, followed by 3 sets of 15 repetitions at 40% 1-MR (maximal repetition), interspersed with 60 sec of recovery. An arterial occlusion pressure of 50% of systolic pressure will be maintained constant using a digital tourniquet. The cuff will be deflated during the recovery phases. In the control group (RT group) it will be the same intervention with same intensities but without using BFR.

    Also known as: Resistance training

06

What researchers measure

Primary outcomes

  1. RT control group

    Left ventricular global longitudinal strain (GLS), calculated from segmental longitudinal strains on apical 4-, 3-, and 2-chamber views using an 18-segment model (Voigt et al 2015).

    Time frame: Baseline

  2. BFR+RT group

    Left ventricular global longitudinal strain (GLS), calculated from segmental longitudinal strains on apical 4-, 3-, and 2-chamber views using an 18-segment model (Voigt et al 2015).

    Time frame: Baseline

  3. RT control group

    Left ventricular global longitudinal strain (GLS), calculated from segmental longitudinal strains on apical 4-, 3-, and 2-chamber views using an 18-segment model (Voigt et al 2015).

    Time frame: After 4 weeks of rehabilitation

  4. BFR+RT group

    Left ventricular global longitudinal strain (GLS), calculated from segmental longitudinal strains on apical 4-, 3-, and 2-chamber views using an 18-segment model (Voigt et al 2015).

    Time frame: After 4 weeks of rehabilitation

Secondary outcomes

  1. (A) other parameters of left ventricular and atrial myocardial function in the control group: Myocardial work

    The global index (constructive work, lost work, and efficiency) will be measured in mmHg%

    Time frame: Baseline

  2. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Myocardial work

    The global index (constructive work, lost work, and efficiency) will be measured in mmHg%

    Time frame: Baseline

  3. (A) other parameters of left ventricular and atrial myocardial function in the control group: Myocardial work

    The global index (constructive work, lost work, and efficiency) will be measured in mmHg%

    Time frame: After 4 weeks of rehabilitation

  4. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Myocardial work

    The global index (constructive work, lost work, and efficiency) will be measured in mmHg%

    Time frame: After 4 weeks of rehabilitation

  5. (A) other parameters of left ventricular and atrial myocardial function in the control group: Left atrial deformities

    Left atrial deformities will be measured in %

    Time frame: Baseline

  6. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Left atrial deformities

    Left atrial deformities will be measured in %

    Time frame: Baseline

  7. (A) other parameters of left ventricular and atrial myocardial function in the control group: Left atrial deformities

    Left atrial deformities will be measured in %

    Time frame: After 4 weeks of rehabilitation

  8. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Left atrial deformities

    Left atrial deformities will be measured in %

    Time frame: After 4 weeks of rehabilitation

  9. (A) other parameters of left ventricular and atrial myocardial function in the control group: Mechanical dispersion

    Post-systolic contractions will be measured in mmHg%

    Time frame: Baseline

  10. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Mechanical dispersion

    Post-systolic contractions will be measured in mmHg%

    Time frame: Baseline

  11. (A) other parameters of left ventricular and atrial myocardial function in the control group: Mechanical dispersion

    Post-systolic contractions will be measured in mmHg%

    Time frame: After 4 weeks of rehabilitation

  12. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Mechanical dispersion

    Post-systolic contractions will be measured in mmHg%

    Time frame: After 4 weeks of rehabilitation

  13. (A) other parameters of left ventricular and atrial myocardial function in the control group: Left ventricle ejection fraction

    Left ventricle ejection fraction will be measured in %

    Time frame: Baseline

  14. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Left ventricle ejection fraction

    Left ventricle ejection fraction will be measured in %

    Time frame: Baseline

  15. (A) other parameters of left ventricular and atrial myocardial function in the control group: Left ventricle ejection fraction

    Left ventricle ejection fraction will be measured in %

    Time frame: After 4 weeks of rehabilitation

  16. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Left ventricle ejection fraction

    Left ventricle ejection fraction will be measured in %

    Time frame: After 4 weeks of rehabilitation

  17. (A) other parameters of left ventricular and atrial myocardial function in the control group: E/E' and E/A ratio

    E/E' and E/A ratio will be measured

    Time frame: Baseline

  18. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: E/E' and E/A ratio

    E/E' and E/A ratio will be measured

    Time frame: Baseline

  19. (A) other parameters of left ventricular and atrial myocardial function in the control group: E/E' and E/A ratio

    E/E' and E/A ratio will be measured

    Time frame: After 4 weeks of rehabilitation

  20. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RTgroup: E/E' and E/A ratio

    E/E' and E/A ratio will be measured

    Time frame: After 4 weeks of rehabilitation

  21. (A) other parameters of left ventricular and atrial myocardial function in the control group: Cardiac index

    Cardiac index will be measured in L/min/m2

    Time frame: Baseline

  22. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Cardiac index

    Cardiac index will be measured in L/min/m2

    Time frame: Baseline

  23. (A) other parameters of left ventricular and atrial myocardial function in the control group: Cardiac index

    Cardiac index will be measured in L/min/m2

    Time frame: After 4 weeks of rehabilitation

  24. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Cardiac index

    Cardiac index will be measured in L/min/m2

    Time frame: After 4 weeks of rehabilitation

  25. (A) other parameters of left ventricular and atrial myocardial function in the control group: Tricuspid regurgitation flow

    Tricuspid regurgitation flow will be measured in m/sec

    Time frame: Baseline

  26. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Tricuspid regurgitation flow

    Tricuspid regurgitation flow will be measured in m/sec

    Time frame: Baseline

  27. (A) other parameters of left ventricular and atrial myocardial function in the control group: Tricuspid regurgitation flow

    Tricuspid regurgitation flow will be measured in m/sec

    Time frame: After 4 weeks of rehabilitation

  28. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Tricuspid regurgitation flow

    Tricuspid regurgitation flow will be measured in m/sec

    Time frame: After 4 weeks of rehabilitation

  29. (A) other parameters of left ventricular and atrial myocardial function in the control group: systolic pulmonary arterial pressure

    Systolic pulmonary arterial pressure will be measured in mmHg

    Time frame: Baseline

  30. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: systolic pulmonary arterial pressure

    Systolic pulmonary arterial pressure will be measured in mmHg

    Time frame: Baseline

  31. (A) other parameters of left ventricular and atrial myocardial function in the control group: systolic pulmonary arterial pressure (mmHg)

    Systolic pulmonary arterial pressure will be measured in mmHg

    Time frame: After 4 weeks of rehabilitation

  32. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: systolic pulmonary arterial pressure (mmHg)

    Systolic pulmonary arterial pressure will be measured in mmHg

    Time frame: After 4 weeks of rehabilitation

  33. (A) other parameters of left ventricular and atrial myocardial function in the control group: Vmax IT

    Vmax IT will be measured in m/sec

    Time frame: Baseline

  34. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Vmax IT

    Vmax IT will be measured in m/sec

    Time frame: Baseline

  35. (A) other parameters of left ventricular and atrial myocardial function in the control group: Vmax IT

    Vmax IT will be measured in m/sec

    Time frame: After 4 weeks of rehabilitation

  36. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Vmax IT

    Vmax IT will be measured in m/sec

    Time frame: After 4 weeks of rehabilitation

  37. (A) other parameters of left ventricular and atrial myocardial function in the control group: Left ventricular volume

    Left ventricular telesystolic and telediastolic volumes will be measured

    Time frame: Baseline

  38. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Left ventricular volume

    Left ventricular telesystolic and telediastolic volumes will be measured

    Time frame: Baseline

  39. (A) other parameters of left ventricular and atrial myocardial function in the control group: Left ventricular volume

    Left ventricular telesystolic and telediastolic volumes will be measured

    Time frame: After 4 weeks of rehabilitation

  40. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Left ventricular volume

    Left ventricular telesystolic and telediastolic volumes will be measured

    Time frame: After 4 weeks of rehabilitation

  41. (A) other parameters of left ventricular and atrial myocardial function in the control group: Atrial volume

    Atrial telesystolic and telediastolic volumes will be measured

    Time frame: Baseline

  42. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Atrial volume

    Atrial telesystolic and telediastolic volumes will be measured

    Time frame: Baseline

  43. (A) other parameters of left ventricular and atrial myocardial function in the control group: Atrial volume

    Atrial telesystolic and telediastolic volumes will be measured

    Time frame: After 4 weeks of rehabilitation

  44. (A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Atrial volume

    Atrial telesystolic and telediastolic volumes will be measured

    Time frame: After 4 weeks of rehabilitation

  45. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: Myocardial work

    The global index (constructive work, lost work, and efficiency) will be measured in mmHg%

    Time frame: Baseline

  46. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Myocardial work

    The global index (constructive work, lost work, and efficiency) will be measured in mmHg%

    Time frame: Baseline

  47. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: Myocardial work

    The global index (constructive work, lost work, and efficiency) will be measured in mmHg%

    Time frame: After 4 weeks of rehabilitation

  48. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Myocardial work

    The global index (constructive work, lost work, and efficiency) will be measured in mmHg%

    Time frame: After 4 weeks of rehabilitation

  49. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: Left atrial deformities

    Left atrial deformities will be measured in %

    Time frame: Baseline

  50. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Left atrial deformities

    Left atrial deformities will be measured in %

    Time frame: Baseline

  51. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: Left atrial deformities

    Left atrial deformities will be measured in %

    Time frame: After 4 weeks of rehabilitation

  52. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Left atrial deformities

    Left atrial deformities will be measured in %

    Time frame: After 4 weeks of rehabilitation

  53. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: Mechanical dispersion

    Post-systolic contractions will be measured in mmHg%

    Time frame: Baseline

  54. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Mechanical dispersion

    Post-systolic contractions will be measured in mmHg%

    Time frame: Baseline

  55. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: Mechanical dispersion

    Post-systolic contractions will be measured in mmHg%

    Time frame: After 4 weeks of rehabilitation

  56. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Mechanical dispersion

    Post-systolic contractions will be measured in mmHg%

    Time frame: After 4 weeks of rehabilitation

  57. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: Left ventricle ejection fraction

    The left ventricle ejection fraction will be measured as a percentage

    Time frame: Baseline

  58. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Left ventricle ejection fraction

    The left ventricle ejection fraction will be measured as a percentage

    Time frame: Baseline

  59. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: Left ventricle ejection fraction

    The left ventricle ejection fraction will be measured as a percentage

    Time frame: After 4 weeks of rehabilitation

  60. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Left ventricle ejection fraction

    The left ventricle ejection fraction will be measured as a percentage

    Time frame: After 4 weeks of rehabilitation

  61. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: E/E' and E/A ratio

    The E/E' and E/A ratio will be measured

    Time frame: Baseline

  62. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: E/E' and E/A ratio

    The E/E' and E/A ratio will be measured

    Time frame: Baseline

  63. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: E/E' and E/A ratio

    The E/E' and E/A ratio will be measured

    Time frame: After 4 weeks of rehabilitation

  64. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: E/E' and E/A ratio

    The E/E' and E/A ratio will be measured

    Time frame: After 4 weeks of rehabilitation

  65. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: cardiac index

    Cardiac index will be measured in L/min/m2

    Time frame: Baseline

  66. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: cardiac index

    Cardiac index will be measured in L/min/m2

    Time frame: Baseline

  67. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: cardiac index

    Cardiac index will be measured in L/min/m2

    Time frame: After 4 weeks of rehabilitation

  68. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: cardiac index

    Cardiac index will be measured in L/min/m2

    Time frame: After 4 weeks of rehabilitation

  69. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: Tricuspid regurgitation flow

    Tricuspid regurgitation flow will be measured in m/sec

    Time frame: Baseline

  70. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Tricuspid regurgitation flow

    Tricuspid regurgitation flow will be measured in m/sec

    Time frame: Baseline

  71. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: Tricuspid regurgitation flow

    Tricuspid regurgitation flow will be measured in m/sec

    Time frame: After 4 weeks of rehabilitation

  72. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Tricuspid regurgitation flow

    Tricuspid regurgitation flow will be measured in m/sec

    Time frame: After 4 weeks of rehabilitation

  73. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: systolic pulmonary arterial pressure

    Systolic pulmonary arterial pressure will be measured in mmHg

    Time frame: Baseline

  74. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: systolic pulmonary arterial pressure

    Systolic pulmonary arterial pressure will be measured in mmHg

    Time frame: Baseline

  75. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: systolic pulmonary arterial pressure

    Systolic pulmonary arterial pressure will be measured in mmHg

    Time frame: After 4 weeks of rehabilitation

  76. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: systolic pulmonary arterial pressure

    Systolic pulmonary arterial pressure will be measured in mmHg

    Time frame: After 4 weeks of rehabilitation

  77. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: Vmax IT

    Vmax IT will be measured in m/sec

    Time frame: Baseline

  78. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Vmax IT

    Vmax IT will be measured in m/sec

    Time frame: Baseline

  79. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: Vmax IT

    Vmax IT will be measured in m/sec

    Time frame: After 4 weeks of rehabilitation

  80. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Vmax IT

    Vmax IT will be measured in m/sec

    Time frame: After 4 weeks of rehabilitation

  81. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: Atrial volume

    Atrial telesystolic and telediastolic volumes will be measured

    Time frame: Baseline

  82. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Atrial volume

    Atrial telesystolic and telediastolic volumes will be measured

    Time frame: Baseline

  83. (B) Left cardiac remodeling (left ventricle and atrium) in the control group: Atrial volume

    Atrial telesystolic and telediastolic volumes will be measured

    Time frame: After 4 weeks of rehabilitation

  84. (B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Atrial volume

    Atrial telesystolic and telediastolic volumes will be measured

    Time frame: After 4 weeks of rehabilitation

  85. (C) Stress test measurement in controls : peak oxygen consumption

    Peak oxygen consumption (VO2pic) will be measured in mL/min/kg

    Time frame: Baseline

  86. (C) Stress test measurement in the BFR+RT group : peak oxygen consumption

    Peak oxygen consumption (VO2pic) will be measured in mL/min/kg

    Time frame: Baseline

  87. (C) Stress test measurement in controls : peak oxygen consumption

    Peak oxygen consumption (VO2pic) will be measured in mL/min/kg

    Time frame: After 4 weeks of rehabilitation

  88. (C) Stress test measurement in the BFR+RT group: peak oxygen consumption

    Peak oxygen consumption (VO2pic) will be measured in mL/min/kg

    Time frame: After 4 weeks of rehabilitation

  89. (C) Stress test measurement in controls : Maximum aerobic power

    Maximum aerobic power will be measured in Watts * First ventilatory threshold (SV1) mL/min/kg

    Time frame: Baseline

  90. (C) Stress test measurement in the BFR+RT group : Maximum aerobic power

    Maximum aerobic power will be measured in Watts * First ventilatory threshold (SV1) mL/min/kg

    Time frame: Baseline

  91. (C) Stress test measurement in controls : Maximum aerobic power

    Maximum aerobic power will be measured in Watts * First ventilatory threshold (SV1) mL/min/kg

    Time frame: After 4 weeks of rehabilitation

  92. (C) Stress test measurement in the BFR+RT group : Maximum aerobic power

    Maximum aerobic power will be measured in Watts * First ventilatory threshold (SV1) mL/min/kg

    Time frame: After 4 weeks of rehabilitation

  93. (C) Stress test measurement in controls : First ventilatory threshold

    First ventilatory threshold will be measured in mL/min/kg

    Time frame: Baseline

  94. (C) Stress test measurement in the BFR+RT group : First ventilatory threshold

    First ventilatory threshold will be measured in mL/min/kg

    Time frame: Baseline

  95. (C) Stress test measurement in controls : First ventilatory threshold

    First ventilatory threshold will be measured in mL/min/kg

    Time frame: After 4 weeks of rehabilitation

  96. (C) Stress test measurement in the BFR+RT group : First ventilatory threshold

    First ventilatory threshold will be measured in mL/min/kg

    Time frame: After 4 weeks of rehabilitation

  97. (C) Muscular evaluation in controls: Peak torque

    Peak torque will be measured in Nm

    Time frame: Baseline

  98. (C) Muscular evaluation in the BFR+RT group: Peak torque

    Peak torque will be measured in Nm

    Time frame: Baseline

  99. (C) Muscular evaluation in controls: Peak torque

    Peak torque will be measured in Nm

    Time frame: After 4 weeks of rehabilitation

  100. (C) Muscular evaluation in the BFR+RT group: Peak torque

    Peak torque will be measured in Nm

    Time frame: After 4 weeks of rehabilitation

  101. (C) Muscular evaluation in controls: Maximum repetition

    Maximum repetition will be measured in kilograms

    Time frame: Baseline

  102. (C) Muscular evaluation in the BFR+RT group: Maximum repetition

    Maximum repetition will be measured in kilograms

    Time frame: Baseline

  103. (C) Muscular evaluation in controls: Maximum repetition

    Maximum repetition will be measured in kilograms

    Time frame: After 4 weeks of rehabilitation

  104. (C) Muscular evaluation in the BFR+RT group: Maximum repetition

    Maximum repetition will be measured in kilograms

    Time frame: After 4 weeks of rehabilitation

  105. (D) Clinical and biological measurement in controls: Body mass index

    Body mass index will be measured in Kg/m2

    Time frame: Baseline

  106. (D) Clinical and biological measurement in the BFR+RT group: Body mass index

    Body mass index will be measured in Kg/m2

    Time frame: Baseline

  107. (D) Clinical and biological measurement in controls: Body mass index

    Body mass index will be measured in Kg/m2

    Time frame: After 4 weeks of rehabilitation

  108. (D) Clinical and biological measurement in the BFR+RT group: Body mass index

    Body mass index will be measured in Kg/m2

    Time frame: After 4 weeks of rehabilitation

  109. (D) Clinical and biological measurement in controls: Waist circumference

    Waist circumference will be measured in cm

    Time frame: Baseline

  110. (D) Clinical and biological measurement in the BFR+RT group: Waist circumference

    Waist circumference will be measured in cm

    Time frame: Baseline

  111. (D) Clinical and biological measurement in controls: Waist circumference

    Waist circumference will be measured in cm

    Time frame: After 4 weeks of rehabilitation

  112. (D) Clinical and biological measurement in the BFR+RT group: Waist circumference

    Waist circumference will be measured in cm

    Time frame: After 4 weeks of rehabilitation

  113. (D) Clinical and biological measurement in controls: Lipid profile

    Lipids will be measured in mmol/L

    Time frame: Baseline

  114. (D) Clinical and biological measurement in the BFR+RT group: Lipid profile

    Lipids will be measured in mmol/L

    Time frame: Baseline

  115. (D) Clinical and biological measurement in controls: Lipid profile

    Lipids will be measured in mmol/L

    Time frame: After 4 weeks of rehabilitation

  116. (D) Clinical and biological measurement in the BFR+RT group: Lipid profile

    Lipids will be measured in mmol/L

    Time frame: After 4 weeks of rehabilitation

  117. (D) Clinical and biological measurement in controls: Glycated hemoglobin

    Glycated hemoglobin will be measured as a %

    Time frame: Baseline

  118. (D) Clinical and biological measurement in the BFR+RT group: Glycated hemoglobin

    Glycated hemoglobin will be measured as a %

    Time frame: Baseline

  119. (D) Clinical and biological measurement in controls: Glycated hemoglobin

    Glycated hemoglobin will be measured as a %

    Time frame: After 4 weeks of rehabilitation

  120. (D) Clinical and biological measurement in the BFR+RT group: Glycated hemoglobin

    Glycated hemoglobin will be measured as a %

    Time frame: After 4 weeks of rehabilitation

  121. (D) Clinical and biological measurement in controls: Fasting blood glucose

    Fasting blood glucose will be measured in g/L

    Time frame: Baseline

  122. (D) Clinical and biological measurement in the BFR+RT group: Fasting blood glucose

    Fasting blood glucose will be measured in g/L

    Time frame: Baseline

  123. (D) Clinical and biological measurement in controls: Fasting blood glucose

    Fasting blood glucose will be measured in g/L

    Time frame: After 4 weeks of rehabilitation

  124. (D) Clinical and biological measurement in the BFR+RT group: Fasting blood glucose

    Fasting blood glucose will be measured in g/L

    Time frame: After 4 weeks of rehabilitation

  125. (D) Clinical and biological measurement in controls: Pro-Brain Natriuretic Peptide

    Pro-Brain Natriuretic Peptide will be measured in ng/L

    Time frame: Baseline

  126. (D) Clinical and biological measurement in the BFR+RT group: Pro-Brain Natriuretic Peptide

    Pro-Brain Natriuretic Peptide will be measured in ng/L

    Time frame: Baseline

  127. (D) Clinical and biological measurement in controls: Pro-Brain Natriuretic Peptide

    Pro-Brain Natriuretic Peptide will be measured in ng/L

    Time frame: After 4 weeks of rehabilitation

  128. (D) Clinical and biological measurement in the BFR+RT group: Pro-Brain Natriuretic Peptide

    Pro-Brain Natriuretic Peptide will be measured in ng/L

    Time frame: After 4 weeks of rehabilitation

  129. (D) Clinical and biological measurement in controls: C-reactive protein

    C-reactive protein will be measured in mg/L

    Time frame: Baseline

  130. (D) Clinical and biological measurement in the BFR+RT group: C-reactive protein

    C-reactive protein will be measured in mg/L

    Time frame: Baseline

  131. (D) Clinical and biological measurement in controls: C-reactive protein

    C-reactive protein will be measured in mg/L

    Time frame: After 4 weeks of rehabilitation

  132. (D) Clinical and biological measurement in the BFR+RT group: C-reactive protein

    C-reactive protein will be measured in mg/L

    Time frame: After 4 weeks of rehabilitation

  133. (D) Clinical and biological measurement in controls: Micro ribonucleic acids

    Micro ribonucleic acids will be measured in ng/µl

    Time frame: Baseline

  134. (D) Clinical and biological measurement in the BFR+RT group: Micro ribonucleic acids

    Micro ribonucleic acids will be measured in ng/µl

    Time frame: Baseline

  135. (D) Clinical and biological measurement in controls: Micro ribonucleic acid

    Micro ribonucleic acids will be measured in ng/µl

    Time frame: After 4 weeks of rehabilitation

  136. (D) Clinical and biological measurement in the BFR+RT group: Micro ribonucleic acid

    Micro ribonucleic acids will be measured in ng/µl

    Time frame: After 4 weeks of rehabilitation

  137. (E) MacNew Heart Disease Quality of Life score in controls

    The MacNew is a self-administered heart disease-specific health-related quality of life \[HRQL\] questionnaire which addresses 3 major HRQL domains: Emotional, Physical, and Social. Each domain contains 9 questions to be rated as 1 \[not very important\] to 5 \[very important\]. These domains can be combined to give a Global HRQL score

    Time frame: Baseline

  138. (E) MacNew Heart Disease Quality of Life score in the BFR+RT group

    The MacNew is a self-administered heart disease-specific health-related quality of life \[HRQL\] questionnaire which addresses 3 major HRQL domains: Emotional, Physical, and Social. Each domain contains 9 questions to be rated as 1 \[not very important\] to 5 \[very important\]. These domains can be combined to give a Global HRQL score

    Time frame: Baseline

  139. (E) MacNew Heart Disease Quality of Life score in controls

    The MacNew is a self-administered heart disease-specific health-related quality of life \[HRQL\] questionnaire which addresses 3 major HRQL domains: Emotional, Physical, and Social. Each domain contains 9 questions to be rated as 1 \[not very important\] to 5 \[very important\]. These domains can be combined to give a Global HRQL score

    Time frame: After 4 weeks of rehabilitation

  140. (E) MacNew Heart Disease Quality of Life score in the BFR+RT group

    The MacNew is a self-administered heart disease-specific health-related quality of life \[HRQL\] questionnaire which addresses 3 major HRQL domains: Emotional, Physical, and Social. Each domain contains 9 questions to be rated as 1 \[not very important\] to 5 \[very important\]. These domains can be combined to give a Global HRQL score

    Time frame: After 4 weeks of rehabilitation

  141. (F) International Physical Activity Questionnaire in controls

    The International Physical Activity Questionnaire is intended for people aged 15 and over. The questionnaire assesses overall physical activity and sedentary time over the last seven days. The questionnaire looks at vigorous and moderate activity, walking, and time spent sitting (sedentary lifestyle), whether during leisure activities, at work, in daily life or during transport. There are several versions of the questionnaire, including a short one (7 questions) and a long one (27 questions), which people can self-administer or answer by telephone, for example. The questionnaire classifies the subject according to 3 levels of activity: inactive, moderate, high.

    Time frame: Baseline

  142. (F) International Physical Activity Questionnaire in the BFR+RT group

    The International Physical Activity Questionnaire is intended for people aged 15 and over. The questionnaire assesses overall physical activity and sedentary time over the last seven days. The questionnaire looks at vigorous and moderate activity, walking, and time spent sitting (sedentary lifestyle), whether during leisure activities, at work, in daily life or during transport. There are several versions of the questionnaire, including a short one (7 questions) and a long one (27 questions), which people can self-administer or answer by telephone, for example. The questionnaire classifies the subject according to 3 levels of activity: inactive, moderate, high.

    Time frame: Baseline

  143. (F) International Physical Activity Questionnaire in controls

    The International Physical Activity Questionnaire is intended for people aged 15 and over. The questionnaire assesses overall physical activity and sedentary time over the last seven days. The questionnaire looks at vigorous and moderate activity, walking, and time spent sitting (sedentary lifestyle), whether during leisure activities, at work, in daily life or during transport. There are several versions of the questionnaire, including a short one (7 questions) and a long one (27 questions), which people can self-administer or answer by telephone, for example. The questionnaire classifies the subject according to 3 levels of activity: inactive, moderate, high.

    Time frame: After 4 weeks of rehabilitation

  144. (F) International Physical Activity Questionnaire in the BFR+RT group

    The International Physical Activity Questionnaire is intended for people aged 15 and over. The questionnaire assesses overall physical activity and sedentary time over the last seven days. The questionnaire looks at vigorous and moderate activity, walking, and time spent sitting (sedentary lifestyle), whether during leisure activities, at work, in daily life or during transport. There are several versions of the questionnaire, including a short one (7 questions) and a long one (27 questions), which people can self-administer or answer by telephone, for example. The questionnaire classifies the subject according to 3 levels of activity: inactive, moderate, high.

    Time frame: After 4 weeks of rehabilitation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ambrosetti M, Abreu A, Corra U, Davos CH, Hansen D, Frederix I, Iliou MC, Pedretti RFE, Schmid JP, Vigorito C, Voller H, Wilhelm M, Piepoli MF, Bjarnason-Wehrens B, Berger T, Cohen-Solal A, Cornelissen V, Dendale P, Doehner W, Gaita D, Gevaert AB, Kemps H, Kraenkel N, Laukkanen J, Mendes M, Niebauer J, Simonenko M, Zwisler AO. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2021 May 14;28(5):460-495. doi: 10.1177/2047487320913379. PubMed 33611446 ↗
  • Badano LP, Kolias TJ, Muraru D, Abraham TP, Aurigemma G, Edvardsen T, D'Hooge J, Donal E, Fraser AG, Marwick T, Mertens L, Popescu BA, Sengupta PP, Lancellotti P, Thomas JD, Voigt JU; Industry representatives; Reviewers: This document was reviewed by members of the 2016-2018 EACVI Scientific Documents Committee. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2018 Jun 1;19(6):591-600. doi: 10.1093/ehjci/jey042. PubMed 29596561 ↗
  • Beckers PJ, Denollet J, Possemiers NM, Wuyts FL, Vrints CJ, Conraads VM. Combined endurance-resistance training vs. endurance training in patients with chronic heart failure: a prospective randomized study. Eur Heart J. 2008 Aug;29(15):1858-66. doi: 10.1093/eurheartj/ehn222. Epub 2008 May 30. PubMed 18515805 ↗
  • Bigot M, Guy JM, Monpere C, Cohen-Solal A, Pavy B, Iliou MC, Bosser G, Corone S, Douard H, Farrokhi T, Guerder A, Guillo P, Houppe JP, Pezel T, Pierre B, Roueff S, Thomas D, Verges B, Blanchard JC, Ghannem M, Marcadet D. Cardiac rehabilitation recommendations of the Group Exercise Rehabilitation Sports - Prevention (GERS-P) of the French Society of Cardiology: 2023 update. Arch Cardiovasc Dis. 2024 Aug-Sep;117(8-9):521-541. doi: 10.1016/j.acvd.2024.05.119. Epub 2024 Jul 4. No abstract available. PubMed 39174436 ↗
  • Billah M, Ridiandries A, Allahwala U, Mudaliar H, Dona A, Hunyor S, Khachigian LM, Bhindi R. Circulating mediators of remote ischemic preconditioning: search for the missing link between non-lethal ischemia and cardioprotection. Oncotarget. 2019 Jan 4;10(2):216-244. doi: 10.18632/oncotarget.26537. eCollection 2019 Jan 4. PubMed 30719216 ↗
  • Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation. 1997 Sep 2;96(5):1641-6. doi: 10.1161/01.cir.96.5.1641. PubMed 9315559 ↗
  • Botker HE, Lassen TR, Jespersen NR. Clinical translation of myocardial conditioning. Am J Physiol Heart Circ Physiol. 2018 Jun 1;314(6):H1225-H1252. doi: 10.1152/ajpheart.00027.2018. Epub 2018 Mar 2. PubMed 29498531 ↗
  • Cahalin LP, Formiga MF, Owens J, Anderson B, Hughes L. Beneficial Role of Blood Flow Restriction Exercise in Heart Disease and Heart Failure Using the Muscle Hypothesis of Chronic Heart Failure and a Growing Literature. Front Physiol. 2022 Jul 6;13:924557. doi: 10.3389/fphys.2022.924557. eCollection 2022. PubMed 35874535 ↗
  • Caminiti G, Volterrani M, Iellamo F, Marazzi G, Silvestrini M, Giamundo DM, Morsella V, Di Biasio D, Franchini A, Perrone MA. Exercise training for patients with heart failure and preserved ejection fraction. A narrative review. Monaldi Arch Chest Dis. 2025 Oct 14;95(3). doi: 10.4081/monaldi.2024.3030. Epub 2024 Jul 23. PubMed 39058025 ↗
  • Chen YC, Chen WC, Liu CW, Huang WY, Lu I, Lin CW, Huang RY, Chen JS, Huang CH. Is moderate resistance training adequate for older adults with sarcopenia? A systematic review and network meta-analysis of RCTs. Eur Rev Aging Phys Act. 2023 Nov 29;20(1):22. doi: 10.1186/s11556-023-00333-4. PubMed 38030985 ↗
  • Danduboyina A, Panjiyar BK, Borra SR, Panicker SS. Cardiovascular Benefits of Resistance Training in Patients With Heart Failure With Reduced Ejection Fraction: A Systematic Review. Cureus. 2023 Oct 27;15(10):e47813. doi: 10.7759/cureus.47813. eCollection 2023 Oct. PubMed 38021681 ↗
  • Eser P, Trachsel LD, Marcin T, Herzig D, Freiburghaus I, De Marchi S, Zimmermann AJ, Schmid JP, Wilhelm M. Short- and Long-Term Effects of High-Intensity Interval Training vs. Moderate-Intensity Continuous Training on Left Ventricular Remodeling in Patients Early After ST-Segment Elevation Myocardial Infarction-The HIIT-EARLY Randomized Controlled Trial. Front Cardiovasc Med. 2022 Jun 17;9:869501. doi: 10.3389/fcvm.2022.869501. eCollection 2022. PubMed 35783836 ↗
  • Fayol A, Wack M, Livrozet M, Carves JB, Domenge O, Vermersch E, Mirabel M, Karras A, Le Guen J, Blanchard A, Azizi M, Amar L, Bories MC, Mousseaux E, Carette C, Puymirat E, Hagege A, Jannot AS, Hulot JS. Aetiological classification and prognosis in patients with heart failure with preserved ejection fraction. ESC Heart Fail. 2022 Feb;9(1):519-530. doi: 10.1002/ehf2.13717. Epub 2021 Nov 29. PubMed 34841727 ↗
  • Ferraz RB, Gualano B, Rodrigues R, Kurimori CO, Fuller R, Lima FR, DE Sa-Pinto AL, Roschel H. Benefits of Resistance Training with Blood Flow Restriction in Knee Osteoarthritis. Med Sci Sports Exerc. 2018 May;50(5):897-905. doi: 10.1249/MSS.0000000000001530. PubMed 29266093 ↗
  • Junior AF, Schamne JC, Perandini LAB, Chimin P, Okuno NM. Effects of Walking Training with Restricted Blood Flow on HR and HRV Kinetics and HRV Recovery. Int J Sports Med. 2019 Sep;40(9):585-591. doi: 10.1055/a-0942-7479. Epub 2019 Jul 4. PubMed 31272111 ↗
  • Kambic T, Jug B, Piepoli MF, Lainscak M. Is blood flow restriction resistance training the missing piece in cardiac rehabilitation of frail patients? Eur J Prev Cardiol. 2023 Jan 24;30(2):117-122. doi: 10.1093/eurjpc/zwac048. No abstract available. PubMed 35253869 ↗
  • Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70. doi: 10.1093/ehjci/jev014. PubMed 25712077 ↗
  • Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, Coats AJ, Dalal H, Rees K, Singh SJ, Taylor RS. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev. 2019 Jan 29;1(1):CD003331. doi: 10.1002/14651858.CD003331.pub5. PubMed 30695817 ↗
  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. No abstract available. PubMed 34447992 ↗
  • Morris BA, Sinaei R, Smart NA. Resistance is not futile: a systematic review of the benefits, mechanisms and safety of resistance training in people with heart failure. Heart Fail Rev. 2024 Jul;29(4):827-839. doi: 10.1007/s10741-024-10402-0. Epub 2024 Apr 15. PubMed 38619757 ↗
  • Murray J, Bennett H, Bezak E, Perry R, Boyle T. The effect of exercise on left ventricular global longitudinal strain. Eur J Appl Physiol. 2022 Jun;122(6):1397-1408. doi: 10.1007/s00421-022-04931-5. Epub 2022 Mar 16. PubMed 35296909 ↗
  • Naderi-Boldaji V, Joukar S, Noorafshan A, Raji-Amirhasani A, Naderi-Boldaji S, Bejeshk MA. The effect of blood flow restriction along with low-intensity exercise on cardiac structure and function in aging rat: Role of angiogenesis. Life Sci. 2018 Sep 15;209:202-209. doi: 10.1016/j.lfs.2018.08.015. Epub 2018 Aug 7. PubMed 30096385 ↗
  • Patterson SD, Hughes L, Warmington S, Burr J, Scott BR, Owens J, Abe T, Nielsen JL, Libardi CA, Laurentino G, Neto GR, Brandner C, Martin-Hernandez J, Loenneke J. Blood Flow Restriction Exercise: Considerations of Methodology, Application, and Safety. Front Physiol. 2019 May 15;10:533. doi: 10.3389/fphys.2019.00533. eCollection 2019. PubMed 31156448 ↗
  • Russell K, Eriksen M, Aaberge L, Wilhelmsen N, Skulstad H, Remme EW, Haugaa KH, Opdahl A, Fjeld JG, Gjesdal O, Edvardsen T, Smiseth OA. A novel clinical method for quantification of regional left ventricular pressure-strain loop area: a non-invasive index of myocardial work. Eur Heart J. 2012 Mar;33(6):724-33. doi: 10.1093/eurheartj/ehs016. Epub 2012 Feb 6. PubMed 22315346 ↗
  • Tanaka Y, Takarada Y. The impact of aerobic exercise training with vascular occlusion in patients with chronic heart failure. ESC Heart Fail. 2018 Aug;5(4):586-591. doi: 10.1002/ehf2.12285. Epub 2018 Mar 25. PubMed 29575708 ↗
  • Trachsel LD, David LP, Gayda M, Henri C, Hayami D, Thorin-Trescases N, Thorin E, Blain MA, Cossette M, Lalonge J, Juneau M, Nigam A. The impact of high-intensity interval training on ventricular remodeling in patients with a recent acute myocardial infarction-A randomized training intervention pilot study. Clin Cardiol. 2019 Dec;42(12):1222-1231. doi: 10.1002/clc.23277. Epub 2019 Oct 10. PubMed 31599994 ↗
  • Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, Pedri S, Ito Y, Abe Y, Metz S, Song JH, Hamilton J, Sengupta PP, Kolias TJ, d'Hooge J, Aurigemma GP, Thomas JD, Badano LP. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. J Am Soc Echocardiogr. 2015 Feb;28(2):183-93. doi: 10.1016/j.echo.2014.11.003. PubMed 25623220 ↗
  • Caminiti G, Volterrani M, Iellamo F, Marazzi G, Manzi V, D'Antoni V, Vadala S, Di Biasio D, Catena M, Morsella V, Perrone MA. Changes in left atrial function following two regimens of combined exercise training in patients with ischemic cardiomyopathy: a pilot study. Front Cardiovasc Med. 2024 May 7;11:1377958. doi: 10.3389/fcvm.2024.1377958. eCollection 2024. PubMed 38774661 ↗
  • Wu P, Liu Y. The Clinical Effects of Pharmacotherapy Combined with Blood Flow Restriction and Isometric Exercise Training in Rehabilitating Patients with Heart Failure with Reduced Ejection Fraction. Rejuvenation Res. 2024 Feb;27(1):33-40. doi: 10.1089/rej.2023.0070. PubMed 38308476 ↗
  • Zhang D, Shen X, Qi X. Resting heart rate and all-cause and cardiovascular mortality in the general population: a meta-analysis. CMAJ. 2016 Feb 16;188(3):E53-E63. doi: 10.1503/cmaj.150535. Epub 2015 Nov 23. PubMed 26598376 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 24 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Aug 2025 → Dec 2025, primary completion Aug 2027 → Dec 2027 and completion Sep 2027 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Aug 12, 2025
StartActual
Dec 5, 2025was Aug 2025
Primary completionEst.
Dec 5, 2027was Aug 2027
CompletionEst.
Jan 5, 2028was Sep 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
Nîmes University Hospital is now Recruiting
Oct 21, 2026
Start date
Aug 1, 2025→Dec 5, 2025 (actual)
Oct 21, 2026
Primary completion
Aug 1, 2027→Dec 5, 2027
Oct 21, 2026
Study completion
Sep 1, 2027→Jan 5, 2028
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Recruiting
    Nîmes University Hospital is now Recruiting
    Start date Aug 1, 2025→Dec 5, 2025 (now actual)
    Primary completion Aug 1, 2027→Dec 5, 2027
    Study completion Sep 1, 2027→Jan 5, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07118410
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Dec 5, 2025
Primary completion
Dec 5, 2027 (estimated)
Completion
Jan 5, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Clarisse BELVISI
Contact
clarisse.belvisi@chu-nimes.fr
+33466683459
Anissa MEGZARI
Contact
drc@chu-nimes.fr
0466684236
Christelle ROBERT, Dr.
study director · Nîmes University Hospital
Alice GAUTHIER, Dr.
principal investigator · Nîmes University Hospital
Clara GROMOFF, Dr.
principal investigator · Nîmes University Hospital
Bertrand LEDERMANN, Dr.
principal investigator · Nîmes University Hospital
Philippe OBERT, Dr.
principal investigator · UFR Sciences Technologies Centre INRAE, Avignon

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion